Description

Simple

Clinical

Overview

Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent. Fendiline is non-selective.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Fendiline
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2,4-thiazolidinedione
The risk or severity of hypoglycemia can be increased when Fendiline is combined with 2,4-thiazolidinedione.
Abafungin
The therapeutic efficacy of Abafungin can be increased when used in combination with Fendiline.
Abexinostat
The risk or severity of QTc prolongation can be increased when Fendiline is combined with Abexinostat.
Acarbose
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Acarbose.
Acebutolol
The risk or severity of bradycardia can be increased when Acebutolol is combined with Fendiline.
Aceclofenac
The risk or severity of hyperkalemia can be increased when Aceclofenac is combined with Fendiline.
Acemetacin
The risk or severity of hyperkalemia can be increased when Fendiline is combined with Acemetacin.
Acepromazine
The risk or severity of hypotension can be increased when Acepromazine is combined with Fendiline.
Aceprometazine
The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Fendiline.
Acetohexamide
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Acetohexamide.
Acetyldigitoxin
Fendiline may increase the arrhythmogenic activities of Acetyldigitoxin.
Acetyldigoxin
Fendiline may increase the arrhythmogenic activities of Acetyldigoxin.
Acetylsalicylic acid
The risk or severity of hyperkalemia can be increased when Acetylsalicylic acid is combined with Fendiline.
Acrivastine
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Fendiline.
Adenosine
Adenosine may increase the arrhythmogenic activities of Fendiline.
Agmatine
Agmatine may increase the arrhythmogenic activities of Fendiline.
AICA ribonucleotide
The risk or severity of hypoglycemia can be increased when Fendiline is combined with AICA ribonucleotide.
Ajmaline
Ajmaline may increase the arrhythmogenic activities of Fendiline.
Albaconazole
The therapeutic efficacy of Albaconazole can be increased when used in combination with Fendiline.
Albiglutide
The risk or severity of hypoglycemia can be increased when Fendiline is combined with Albiglutide.